{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:10:05Z","timestamp":1795018205550,"version":"4.10.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001209","name":"Knights Templar Eye Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.mayocpiqo.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:37:21Z","timestamp":1719391041000},"page":"364-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6632-566X","authenticated-orcid":false,"given":"Nithya","family":"Boopathiraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella V.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syril K.","family":"Dorairaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darby D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocpiqo.2024.05.003_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections","volume":"102","author":"Bourne","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0161-6420(01)00754-0","article-title":"Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration","volume":"108","author":"Brody","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib5","first-page":"182","article-title":"The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity","volume":"36","author":"Klein","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2005.12.013","article-title":"Prevalence of age-related macular degeneration in 4 racial\/ethnic groups in the multi-ethnic study of atherosclerosis","volume":"113","author":"Klein","year":"2006","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2024.05.003_bib7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2024.05.003_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archopht.1997.01100150743009","article-title":"Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainres.2017.07.025","article-title":"Retinal metabolism: a comparative look at energetics in the retina","volume":"1672","author":"Country","year":"2017","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.4266","article-title":"Mechanisms of age-related macular degeneration and therapeutic opportunities","volume":"232","author":"van Lookeren Campagne","year":"2014","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2016.03.001","article-title":"Targeting the complement system for the management of retinal inflammatory and degenerative diseases","volume":"787","author":"Xu","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"10.1016\/j.mayocpiqo.2024.05.003_bib13","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.3390\/ijms22136851","article-title":"Complement system and potential therapeutics in age-related macular degeneration","volume":"22","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2011.09.027","article-title":"Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis","volume":"119","author":"Rudnicka","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2015.04.003","article-title":"Incidence of late-stage age-related macular degeneration in American Whites: systematic review and meta-analysis","volume":"160","author":"Rudnicka","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib17","first-page":"225","article-title":"Smoking and age-related macular degeneration","volume":"63","author":"Houston","year":"2001","journal-title":"Am Fam Phys"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4103\/0301-4738.120218","article-title":"Dietary and lifestyle risk factors associated with age-related macular degeneration: a hospital based study","volume":"61","author":"Nidhi","year":"2013","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ajo.2011.02.025","article-title":"Risk factors for four-year incidence and progression of age-related macular degeneration: the los angeles latino eye study","volume":"152","author":"Choudhury","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib20","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1167\/iovs.14-14299","article-title":"Nongenetic risk factors for neovascular age-related macular degeneration","volume":"55","author":"Ristau","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00055735-200206000-00007","article-title":"Risk factors for age-related macular degeneration: an update","volume":"13","author":"Hyman","year":"2002","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib22","article-title":"Smoking and age-related macular degeneration: review and update","volume":"2013","author":"Velilla","year":"2013","journal-title":"J\u00a0Ophthalmol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archopht.118.3.351","article-title":"Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group","volume":"118","author":"Hyman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2024.05.003_bib24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ophtha.2003.11.010","article-title":"Risk factors for incident age-related macular degeneration: pooled findings from 3 continents","volume":"111","author":"Tomany","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A\u00a0large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archopht.125.1.55","article-title":"A\u00a0prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors","volume":"125","author":"Schaumberg","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib27","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.ophtha.2013.07.053","article-title":"Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium","volume":"120","author":"Buitendijk","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.05.003_bib28","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2016.05.043","article-title":"Validating the AREDS simplified severity scale of age-related macular degeneration with 5- and 10-year incident data in a population-based sample","volume":"123","author":"Liew","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0039-6257(99)00072-7","article-title":"Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression","volume":"44","author":"Abdelsalam","year":"1999","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2024.05.003_bib30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.eye.6702151","article-title":"Characteristics of progression of early age-related macular degeneration: the cardiovascular health and age-related maculopathy study","volume":"21","author":"Tikellis","year":"2007","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib32","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0161-6420(02)01146-6","article-title":"Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study","volume":"109","author":"Klein","year":"2002","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.05.003_bib33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archophthalmol.2009.198","article-title":"Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26","volume":"127","author":"Lindblad","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2024.05.003_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0002-9394(01)01218-1","article-title":"The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report number 6","volume":"132","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib35","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ophtha.2013.03.029","article-title":"Incidence and progression of geographic atrophy: observations from a population-based cohort","volume":"120","author":"Joachim","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.05.003_bib36","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0161-6420(99)90340-8","article-title":"Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration","volume":"106","author":"Sunness","year":"1999","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib37","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1167\/iovs.14-14802","article-title":"Quantitative autofluorescence and cell density maps of the human retinal pigment epithelium","volume":"55","author":"Ach","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib38","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1167\/iovs.11-7457","article-title":"Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration","volume":"52","author":"Schmitz-Valckenberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.05.003_bib39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/bjo.2006.095109","article-title":"Fundus autofluorescence in exudative age-related macular degeneration","volume":"91","author":"McBain","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/IAE.0b013e3181b8348b","article-title":"Fundus autofluorescence (488 NM) and near-infrared autofluorescence (787 NM) visualize different retinal pigment epithelium alterations in patients with age-related macular degeneration","volume":"30","author":"Kellner","year":"2010","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib41","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00417-007-0574-9","article-title":"Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images","volume":"245","author":"Vujosevic","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2024.05.003_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3928\/15428877-20060901-08","article-title":"Fundus autofluorescence before and after photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration","volume":"37","author":"Framme","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.05.003_bib43","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.4238\/2013.December.2.11","article-title":"Fundus autofluorescence in exudative age-related macular degeneration","volume":"12","author":"Peng","year":"2013","journal-title":"Genet Mol Res"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0039-6257(00)00123-5","article-title":"Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography","volume":"45","author":"Desmettre","year":"2000","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib45","article-title":"Low-reflectivity drusen with overlying RPE damage revealed by spectral-domain OCT: hint for the development of age-related macular Degeneration","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib46","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.ophtha.2016.08.047","article-title":"Optical coherence tomography reflective drusen substructures predict progression to geographic atrophy in age-related macular degeneration","volume":"123","author":"Veerappan","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib47","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1016\/j.ophtha.2013.05.029","article-title":"Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration","volume":"120","author":"Ouyang","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2017.08.033","article-title":"Cuticular drusen: clinical phenotypes and natural history defined using multimodal imaging","volume":"125","author":"Balaratnasingam","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101017","article-title":"Reticular pseudodrusen: a critical phenotype in age-related macular degeneration","volume":"88","author":"Wu","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib50","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.ophtha.2015.08.029","article-title":"Ultrahigh-speed, swept-source optical coherence tomography angiography in nonexudative age-related macular degeneration with geographic atrophy","volume":"122","author":"Choi","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib51","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.annepidem.2008.04.002","article-title":"Smoking and the risk of age-related macular degeneration: a meta-analysis","volume":"18","author":"Cong","year":"2008","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib52","article-title":"Nutritional and lifestyle interventions for age-related macular degeneration: a review","volume":"2017","author":"Carneiro","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2024.05.003_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archopht.121.6.785","article-title":"Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio","volume":"121","author":"Seddon","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ajo.2017.10.013","article-title":"Physical activity and age-related macular degeneration: a systematic literature review and meta-analysis","volume":"185","author":"Liu","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ophtha.2016.09.019","article-title":"Mediterranean diet score and its association with age-related macular degeneration: the European Eye Study","volume":"124","author":"Hogg","year":"2017","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2024.05.003_bib56","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ophtha.2020.04.030","article-title":"Adherence to the Mediterranean diet and progression to late age-related macular degeneration in the Age-Related Eye Disease Studies 1 and 2","volume":"127","author":"Keenan","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib57","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A\u00a0randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2024.05.003_bib58","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199404143301501","article-title":"Effect of vitamin-E and beta-carotene on the incidence of lung-cancer and other cancers in male smokers","volume":"330","author":"Heinonen","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.05.003_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083759","article-title":"Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration","volume":"8","author":"Guymer","year":"2013","journal-title":"PLOS ONE"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2024.05.003_bib60","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1167\/iovs.16-21201","article-title":"Beyond VEGF\u2014the Weisenfeld lecture","volume":"57","author":"Miller","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"16","key":"10.1016\/j.mayocpiqo.2024.05.003_bib61","first-page":"1736","article-title":"Age-related macular degeneration\u2014reply","volume":"359","author":"Jager","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib62","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib63","first-page":"198","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib65","article-title":"Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections","volume":"2018","author":"Lau","year":"2018","journal-title":"J\u00a0Ophthalmol"},{"issue":"17","key":"10.1016\/j.mayocpiqo.2024.05.003_bib66","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1517\/14656560802473480","article-title":"Pharmacotherapy of age-related macular degeneration","volume":"9","author":"Ahmadi","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2024.05.003_bib68","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","article-title":"A\u00a0systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration","volume":"100","author":"Chin-Yee","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib69","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1442-9071.2008.01873.x","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment","volume":"36","author":"Fong","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/aos.12463","article-title":"Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration","volume":"92","author":"Broadhead","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.mayocpiqo.2024.05.003_bib71","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.05.003_bib72","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Zarranz-Ventura","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000329473","article-title":"Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study","volume":"226","author":"Silva","year":"2011","journal-title":"Ophthalmologica"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib74","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib75","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.05.003_bib76","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/02713683.2021.1874023","article-title":"Endophthalmitis following intravitreal anti-vascular endothelial growth factor therapy: changes in incidence and outcomes over a 9-year period","volume":"46","author":"Pancholy","year":"2021","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79377-w","article-title":"Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics","volume":"10","author":"Morioka","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.05.003_bib78","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12886-020-01420-1","article-title":"Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics","volume":"20","author":"Shrestha","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.mayocpiqo.2024.05.003_bib80","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein\u00a0+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.05.003_bib81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.05.003_bib82","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2024.05.003_bib83","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/archopht.126.5.608","article-title":"Outcomes of the veterans affairs low vision intervention trial (LOVIT)","volume":"126","author":"Stelmack","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2024.05.003_bib84","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ophtha.2006.07.010","article-title":"Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results","volume":"113","author":"Hudson","year":"2006","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.05.003_bib85","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.ophtha.2011.02.012","article-title":"Comparative effectiveness and cost-effectiveness of the implantable miniature telescope","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2024.05.003_bib86","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archopht.120.8.1041","article-title":"Effect of depression on vision function in age-related macular degeneration","volume":"120","author":"Rovner","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2024.05.003_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICU.0000000000000657","article-title":"Age-related macular degeneration therapy: a review","volume":"31","author":"Ammar","year":"2020","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454824000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454824000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T18:42:16Z","timestamp":1723315336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454824000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2542454824000316"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.05.003","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}